BioLife Solutions, Inc. (BLFS)
- Previous Close
15.86 - Open
15.83 - Bid 15.49 x 200
- Ask 15.57 x 100
- Day's Range
15.42 - 16.01 - 52 Week Range
8.92 - 24.50 - Volume
190,374 - Avg. Volume
368,529 - Market Cap (intraday)
703.962M - Beta (5Y Monthly) 1.69
- PE Ratio (TTM)
-- - EPS (TTM)
-1.52 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.13
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
www.biolifesolutions.comRelated News
Performance Overview: BLFS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLFS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLFS
Valuation Measures
Market Cap
718.00M
Enterprise Value
709.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.84
Price/Book (mrq)
2.13
Enterprise Value/Revenue
4.95
Enterprise Value/EBITDA
-15.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-46.37%
Return on Assets (ttm)
-8.33%
Return on Equity (ttm)
-18.93%
Revenue (ttm)
143.27M
Net Income Avi to Common (ttm)
-66.43M
Diluted EPS (ttm)
-1.52
Balance Sheet and Cash Flow
Total Cash (mrq)
51.7M
Total Debt/Equity (mrq)
12.64%
Levered Free Cash Flow (ttm)
-5.1M
Research Analysis: BLFS
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: BLFS
BLFS: Lowering target price to $17.00
BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetBLFS: Raising target price to $19.00
BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetBLFS: Lowering target price to $18.00
BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetBLFS: What does Argus have to say about BLFS?
BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice Target